98 related articles for article (PubMed ID: 27789684)
1. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15.
Bissio E; Barbás MG; Bouzas MB; Cudolá A; Salomón H; Espínola L; Fernández Giuliano S; Kademián S; Mammana L; Ornani ML; Ravasi G; Vila M; Zapiola I; Falistocco C
J Antimicrob Chemother; 2017 Feb; 72(2):504-510. PubMed ID: 27789684
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
Bissio E; Barbás MG; Kademián S; Bouzas MB; Salomón H; Cudolá A; Giuliano SF; Falistocco C
Antivir Ther; 2017; 22(7):625-629. PubMed ID: 28234630
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
[TBL] [Abstract][Full Text] [Related]
4. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
Yendewa GA; Sahr F; Lakoh S; Ruiz M; Patiño L; Tabernilla A; Deen GF; Sesay M; Salata RA; Poveda E
J Antimicrob Chemother; 2019 Jul; 74(7):2024-2029. PubMed ID: 30989237
[TBL] [Abstract][Full Text] [Related]
6. Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina.
Cecchini D; Sfalcin J; Zapiola I; Gómez A; Fernández Giuliano S; Mammana L; Seravalle A; Rodríguez C; Fay F; Bouzas MB
Rev Esp Quimioter; 2021 Aug; 34(4):371-375. PubMed ID: 34085506
[TBL] [Abstract][Full Text] [Related]
7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
8. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
9. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
10. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
11. Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009.
Youmans E; Tripathi A; Albrecht H; Gibson JJ; Duffus WA
South Med J; 2011 Feb; 104(2):95-101. PubMed ID: 21206421
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
14. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): results from a cohort study in Argentina.
Rozenszajn M; Arazi-Caillaud S; Taicz M; Bologna R; Mangano A; Aulicino PC
J Antimicrob Chemother; 2022 Jun; 77(7):1969-1973. PubMed ID: 35512329
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
[TBL] [Abstract][Full Text] [Related]
18. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India.
Neogi U; Gupta S; Palchaudhuri R; Rao SD; Shastri S; Diwan V; Laishram RS; De Costa A; Shet A
Antivir Ther; 2014; 19(8):813-8. PubMed ID: 24699043
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
20. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
